J&J Psoriasis Pill In A Tier Of Its Own After Phase III Win

The US healthcare giant says that icotrokinra could provide an “industry-leading combination of significant skin clearance with demonstrated tolerability in a once-daily pill" after succeeding in late-stage trials.

Leadership concept, One leader red sphere leads other boxes
• Source: Shutterstock

Johnson & Johnson is preparing regulatory submissions for icotrokinra, its first-in-class oral therapy for psoriasis, after the drug hit its main goals in two Phase III studies.

Key Takeaways

J&J's interleukin-23 receptor blocker has hit in two Phase III psoriasis trials, with regulatory filings planned.

The once-daily pill could provide strong competition to BMS's TYK2 inhibitor Sotyktu and a head-to-head study is ongoing.

Originator Protagonist Therapeutics is now set to receive $165m in milestone payments in the first quarter of 2025.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Four Chinese Firms Snag Global First-In-Class Approvals In China

 

Four Chinese companies have won approvals in China, the first anywhere, for their novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A, respectively.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By 

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

More from Immunological

Vor Is Reborn With New CEO And Ambitious RemeGen Autoimmune Pact

 
• By 

The biotech had been looking at options to survive since May.

Sanofi Links Up Again With Formation To Take Gusacitinib Down New Path

 
• By 

Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.